期刊文献+

左卡尼汀联合多烯磷脂酰胆碱对酒精性肝病的疗效 被引量:7

Therapeutic Efficacy of Levocarnitine Combined with Polyene Phosphatidylcholine on Patients with Alcoholic Liver Disease
在线阅读 下载PDF
导出
摘要 目的:探讨左卡尼汀联合多烯磷脂酰胆碱治疗酒精性肝病患者的临床疗效。方法:选取酒精性肝病患者80例,随机分为治疗组与对照组,治疗组采用左卡尼汀与多烯磷脂酰胆碱联合治疗,对照组采用多烯磷脂酰胆碱治疗,疗程4周,观察治疗前后患者的症状体征、肝功能指标及肝脏纤维化指标的变化。结果:治疗4周后,对照组的总有效率为80.0%,对照组的总有效率为95.0%,两组比较差异有统计学意义(P<0.05);两组患者治疗前肝功能指标和肝纤维化指标无明显差异(P﹥0.05),治疗后与治疗前比较,差异有统计学意义(P<0.05);治疗4周后治疗组与对照组比较,肝功能指标和肝纤维化指标改善更加明显,差异有统计学意义(P<0.05)。结论:左卡尼汀联合多烯磷脂酰胆碱治疗酒精性肝病,能够有效改善患者肝功能以及延缓肝纤维化进程,值得临床推广使用。 Objective:To investigate the clinical effects of levocarnitine combined with polyene phos-phatidylcholine on the treatment of alcoholic liver disease. Method:Eighty patients diagnosed with al-coholic liver disease were divided randomly into two groups,therapeutic group and control group. Therapeutic group received treatment of levocarnitine combined with polyene phosphatidylcholine, while control group was treated with polyene phosphatidylcholine treatment;both groups were treated for 4 weeks. The clinical symptoms and signs,liver functions tests and indexes of hepatic fibrosis were evaluated before and after treatment. Results:After 4 weeksˊtreatment,the therapeutic group got total effective rate of 95 . 0% which was obviously higher than that of control group( 80 . 0%),differences were statistical significant( P﹤0 . 05 ). The indexes of liver functions and hepatic fibrosis had no signif-icant differences before treatment(P﹥0. 05). However,four weeksˊof treatment,comparing therapeu-tic group with control group,indexes of liver functions and hepatic fibrosis had ameliorated obviously, differences were statistically significant( P﹤0 . 05 ). Conclusion:Levocarnitine combined with polyene phosphatidylcholine as treatment for alcoholic liver disease can effectively improve liver function and inhibit the progress of hepatic fibrosis,which should be worthy of promotion.
出处 《贵阳医学院学报》 CAS 2015年第8期882-885,共4页 Journal of Guiyang Medical College
关键词 肝疾病 酒精性 左卡尼汀 磷脂酰胆碱类 liver diseases,alcoholic levocarnitine phosphatidylcholines
  • 相关文献

参考文献9

二级参考文献98

共引文献586

同被引文献108

  • 1杨嘉恩,马晓军,吴晓鹭,洪昱钤,刘家俊.还原型谷胱甘肽治疗酒精性肝病33例疗效观察[J].临床肝胆病杂志,2005,21(1):51-51. 被引量:9
  • 2范毅敏,陈纯,甄宇峰,沈娜君,覃丽君,夏焱.左卡尼汀治疗蒽环类抗肿瘤药物所致心脏毒性的临床观察——附30例报告[J].新医学,2007,38(4):229-231. 被引量:18
  • 3中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J].药品评价,2007,4(2):74-76. 被引量:26
  • 4Robert Ringseis, Janine Keller, Klaus Eder. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity : evidence fix>m in vivo and in vitro Studies with carnitine supplementation and carni-tine deficiency[J]. European Journal of Nutrition,2012,51 (1) :1.
  • 5Mojtaba E,Somayeh B,PaymanA,et al. Carnitine,metabolism,supple-mentation and exercise performance[ J]. Indian Journal of Fundamen-tal and Applied Life Sciences,2011,1 (4) :376.
  • 6Nagababu E, Culyani S, Earley CJ,et al. Iron-deficiency anemia en-hances red blood cell oxidative stress [ J ]. Free Radic Res, 2008,42 (9) :824-829.
  • 7Usberti M.Gerardi G,Bufano G,et al. Effects of erythropoietin and vi-tamin E-modified membrane on plasma oxidative stress markers and a> nemia of hemodialyzed patients[ J]. Am J Kidney Dis,2002,40(3): 590-599.
  • 8Arduini A, Bonomin M, Elaine, et aL Effect of L-camitine administra-tion on erythrocyte survival in haemodialysis patients( J]. Nephrol Dial Transplant,2006,21 (9) :2671-2672.
  • 9陈灏珠,林果为.实用内科学〔M〕.北京:人民卫生出版社, 2009,910-911.
  • 10傅声武,吴国伟,徐文君,等.左卡尼汀在维持性血液透析患者 营养不良治疗中的作用〔J〕.2007年浙沪两地肾脏病学术年会.Lim.

引证文献7

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部